Recently, Odqvist and colleagues reported worse overall survival in PTCL patients associated with nuclear expression of classical or alternative NFKB components, implying that NFKB-inducing kinase (NIK) silencing could be an effective target for abrogating the NIK-dependent NFKB activation [41]. This evidence concerns the gene NFKB1 and mature T-cell and NK-cell non-Hodgkin lymphoma.